Pedro Uson Junior, MD (@PedroUson) profile picture

GI cancer medical oncologist

Phoenix, AZ
Joined May 2020
Pedro Uson Junior, MD retweeted
#ICYMI: Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study by @PedroUson, Samadder et al. https://teapawt.org/t.co/SLfd8QEDM9
1
3
7
Pedro Uson Junior, MD retweeted
Hot off the Press ... Circulating Cell-Free Tumor DNA in Advanced #PancreaticCancer identifies Patients With Worse Overall Survival frontiersin.org/article/10.3… @PedroUson @the_danielahn @drjasonstarr @MiteshBorad @kmody29 @sonbol_bassam @MayoCancerCare @FrontOncology
5
32
Pedro Uson Junior, MD retweeted
Replying to @Aiims1742
@Aiims1742 thank you for sharing the findings of this paper in #pancreaticcancer @MayoCancerCare @PedroUson
Clinical Impact of Pathogenic Germline Variants in #PancreaticCancer journals.lww.com/ctg/Fulltex… All 3 @MayoClinic campuses conducted this study following the @NCCN universal germ line testing guidelines ~15% patients had pathogenic germline variants (BRCA2/ATM most common)
2
7
Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: A multi-center prospective study cghjournal.org/article/S1542…
2
1
1
8
Pedro Uson Junior, MD retweeted
Blinding only one side of the process is problematic. Unblinding reviewers comes w other problems, especially for junior reviewers. Double blinding may be best. Like this piece by @DrNCoburn @VGupta_MD on that issue 👉 journals.lww.com/annalsofsur…
1
6
2
19
Pedro Uson Junior, MD retweeted
Ok...Honeymoon is over & now time to dissect the exciting new data presented @ #ESMO2020 for #GEC #KN590 #CM649 #ATTRCN4 #CM577 1st, thank you to all the pts who participated! & 2nd, congrats to all the investigators involved! It's fantastic to have +ve studies! Lets dive deep:
15
39
14
114
Pedro Uson Junior, MD retweeted
Replying to @agrothey
@agrothey @VPrasadMDMPH No perfect trial design. Limited options in PDAC. POLO trial adds one more and supports a precedent from other BRCA-related cancers. A nicer option over chemotherapy for most patients on a longitudinal basis. A start point to build upon...
Vinay, please.... I have been critical of the POLO trial @EileenMOReilly but this is not “criminal”. We are all trying to move science forward - and POLO with all its faults does that. @OncoAlert
1
9
32
Pedro Uson Junior, MD retweeted
Last but not least #ESMO20 CheckMate577 Given the complex study cohort enrolling >700 patients is a huge accomplishment! Global study 🌎 🤝 Primary endpoint DFS (secondary OS). Primary endpoint reached with HR 0.69 @OncoAlert 🚨 #immunotherapy – at Munich, Germany
Pedro Uson Junior, MD retweeted
Practice changing 3 month+ OS gain for CPS5 patients in CheckMate649 🏆🏆🏆 Biggest study ever in #stomachcancer! Breaking through the one year barrier is meaningful in gastric cancer trials. #ESMO2020
6
57
2
198
Pedro Uson Junior, MD retweeted
#Pancsm #ESMO20 #PancreaticCancer remains a devastating disease. See data presented by @EileenMOReilly discussing negative trials in #pancsm & a potential ways forward. @OncoAlert 🚨 – at Munich, Germany
14
21
Pedro Uson Junior, MD retweeted
Results: CCTG PA.7 in #pancreas #cancer of randomized Gemzar + Nab-P +/- Durvalumab + Treme with no difference in OS (8.8M vs. 9.8M), PFS of (5.4M vs. 5.5M), or RR = 23% vs. 33%. #ESMO20 @PanCAN #clinicaltrials #CancerResearch @VUMC_Cancer @VUMChealth @OncoAlert #immunotherapy
1
10
1
25
Pedro Uson Junior, MD retweeted
Line -1 has a negative connotation for a very positive outcome for Atezo Bev 1st Line Atezo Bev 2nd line Up for grabs Let's not make up lines that are pure fiction
2
1
15